Share Twitter LinkedIn Facebook Email Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In NSCLC After Checkpoint Inhibitor Failure.
Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023] Immunotherapy 2 Mins Read
O-RECIST, iRECIST, ImmunoPET: Assessing Treatment Response – Anna M. Wu, MD – MOASC [2023] Immunotherapy 1 Min Read